Marker

(redirected from biomarker)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Marker

A slang term for documentation indicating that a debt is owed.
References in periodicals archive ?
The global cancer biomarkers market is projected to reach USD 20.
Utilizing public data from the development of multiple ALK inhibitors and the performance characteristics of multiple diagnostic tests for disease relevant biomarkers, Richard Buller will discuss how opportunities for the advancement of regulatory science have evolved and come to fruition in both the drug and diagnostic spaces.
Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics and pharmacogenomics/pharmacogenetics.
A biomarker of vulnerable patients would be a biomarker demonstrating increased concentrations in patients prone to a new cardiac event (i.
The Handbook of Biomarkers is an attempt to create a comprehensive compilation of measurable characteristics used in medicine and/or biomedical research to assess disease or treatment response.
P value does not dictate the importance of a biomarker
Orion's MethylScreen(r) technology leverages biomarkers discovered using its MethylScope technology to develop of a new class of oncology diagnostic kits.
Each step is affected by a person's susceptibility, and the continuum provides multiple opportunities for application of biomarkers for early prediction of disease.
A large number of companies with varying technical backgrounds are involved in biomarkers and 289 of these are profiled in part 2 of the report with classification into various categories.
On the basis of product type, the biomarkers market is segmented into consumables, services, and software.
According to the European Physician and Payer Forum report entitled Securing Favourable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology, considering current reimbursement restrictions, interviewed payers across the EU5 indicate that the price of biomarker-driven therapies, as well as the cost of their companion biomarker tests, will significantly influence the uptake of emerging therapies.